TempraMed Technologies (FRA:9DY) Total Equity: €-1.54 Mil (As of Mar. 2026)


FRA:9DY TempraMed Technologies Ltd FRA:9DY
1 GF Score
Price €0.32
! 5 Warning Signs
View Full Analysis

What is TempraMed Technologies Total Equity?

TempraMed Technologies FRA:9DY +3.96% 1 Total Equity is €-1.54 Mil as of Mar. 2026. GuruFocus rates FRA:9DY with a GF Score™ of 1/100. The stock has 5 warning signs investors should review.

TempraMed Technologies's total equity for the quarter that ended in Mar. 2026 was €-1.54 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

TempraMed Technologies Total Equity Historical Data

* Premium members only.

The historical data trend for TempraMed Technologies's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TempraMed Technologies Total Equity Chart

TempraMed Technologies Annual Data
Trend Dec23 Dec24 Dec25
Total Equity
-0.00 -3.63 -1.60

TempraMed Technologies Quarterly Data
Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only 0.00 -1.14 -0.72 -1.60 -1.54
FRA:9DY
1GF Score
TempraMed Technologies Ltd FRA:9DY
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TempraMed Technologies Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

TempraMed Technologies's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1.573-3.175
=-1.60

TempraMed Technologies's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=1.254-2.79
=-1.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €-1.54 Mil mean?
TempraMed Technologies (FRA:9DY) has a Total Equity of €-1.54 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for TempraMed Technologies and its competitors.
Is TempraMed Technologies' Total Equity too high?
TempraMed Technologies' current Total Equity is €-1.54 Mil. Overall, TempraMed Technologies has a GF Score™ of 1/100, reflecting its overall financial health beyond just this single metric.
How does TempraMed Technologies' Total Equity compare to ABT and SYK?
TempraMed Technologies' Total Equity of €-1.54 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for TempraMed Technologies and its competitors. TempraMed Technologies's current Total Equity is €-1.54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TempraMed Technologies stock overvalued right now?
TempraMed Technologies (FRA:9DY) has a current Total Equity of €-1.54 Mil. The current Total Equity is €-1.54 Mil. TempraMed Technologies' overall GF Score™ is 1/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For TempraMed Technologies (FRA:9DY), the current Total Equity is €-1.54 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TempraMed Technologies Business Description

Other Exchanges VIVI:Canada
Address Heh B’Iyar 14, Tel-Aviv, ISR, 6209307
TempraMed Technologies Ltd through its subsidiary, engaged in developing patent-protected technology designed to serve a broad range of medical and consumer products. TempraMed's primary focus is revolutionizing storage and management of injectable for temperature-sensitive medications. This inventive technology ensures adequate temperature storage conditions to medications without requiring power source or human intervention for years.
1GF Score

Get the complete analysis for FRA:9DY

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.32
Price